Reneo Pharmaceuticals, Inc. (RPHM)
Stock Information
| Ticker Symbol | RPHM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $15.00 |
| CIK Code | 1637715 |
| Employer ID | 47-2309515 |
Company Description
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
Reneo Pharmaceuticals is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
We are initially developing REN001 in three rare genetic diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease).
We completed an open-label Phase 1b clinical trial in patients with PMM and, based on the results, initiated a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in patients with PMM and plan to begin enrollment in the first half of 2021.
We are also conducting two open-label Phase 1b clinical trials of REN001 in patients with LC-FAOD and with McArdle disease and we anticipate results in the first half of 2022.
We also plan to explore the potential of REN001 in other rare diseases, such as Duchenne muscular dystrophy and Alport syndrome.
Key Executives
| Name | Position |
|---|---|
| Gregory J. Flesher | President, Chief Executive Officer and Director |
| Wendy Johnson | Chief Development Officer |
| Alejandro Dorenbaum, M.D. | Chief Medical Officer |
| Vineet R. Jindal | Chief Financial Officer |
| Michael Cruse | Senior Vice President, Corporate Operations |
| Michael Grey | Executive Chairman |
| Lon Cardon, Ph.D. | Director |
| Eric M. Dube, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2021 | 424B4 | Prospectus [Rule 424(b)(4)] |
| Apr 8, 2021 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 9, 2021 | EFFECT | Notice of Effectiveness |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| Apr 8, 2021 | 3 | Initial statement of beneficial ownership of securities |
| View All SEC filings | ||